Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/120613
Title: CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
Author: Martín-Sánchez, Esperanza
Mendaza, Saioa
Ulazia-Garmendia, Ane
Monreal-Santesteban, Iñaki
Blanco-Luquin, Idoia
Córdoba, Alicia
Vicente-García, Francisco
Pérez-Janices, Noemí
Escors, David
Megías, Diego
López-Serra, Paula
Esteller, Manel
Illarramendi, José Juan
Guerrero-Setas, David
Keywords: Metilació
Marcadors bioquímics
Càncer de mama
Epigenètica
Methylation
Biochemical markers
Breast cancer
Epigenetics
Issue Date: 28-Feb-2017
Publisher: Impact Journals
Abstract: The CHL1 gene encodes a cell-adhesion molecule proposed as being a putative tumour-suppressor gene in breast cancer (BC). However, neither the underlying molecular mechanisms nor the clinical value of CHL1 downregulation in BC has been explored. The methylation status of three CpG sites in the CHL1 promoter was analysed by pyrosequencing in neoplastic biopsies from 142 patients with invasive BC and compared with that of non-neoplastic tissues. We found higher CHL1 methylation levels in breast tumours than in non-neoplastic tissues, either from mammoplasties or adjacent-to-tumour, which correlated with lower levels of protein expression in tumours measured by immunohistochemistry. A panel of five BC cell lines was treated with two epigenetic drugs, and restoration of CHL1 expression was observed, indicating in vitro dynamic epigenetic regulation. CHL1 was silenced by shRNA in immortalized but non-neoplastic mammary cells, and enhanced cell proliferation and migration, but not invasion, were found by real-time cell analysis. The prognostic value of CHL1 hypermethylation was assessed by the log-rank test and fitted in a Cox regression model. Importantly, CHL1 hypermethylation was very significantly associated with shorter progression-free survival in our BC patient series, independent of age and stage (p = 0.001). In conclusion, our results indicate that CHL1 is downregulated by hypermethylation and that this epigenetic alteration is an independent prognostic factor in BC.
Note: Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.15004
It is part of: Oncotarget, 2017, vol. 8, num. 9, p. 15789-15801
URI: http://hdl.handle.net/2445/120613
Related resource: https://doi.org/10.18632/oncotarget.15004
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
670727.pdf3.08 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons